灵性增强

灵性增强是指一个人的个人信仰发生转变的体验，这种转变关于他们的存在、他们在宇宙中的位置、与他人的关系，以及他们认为生命中有意义的东西。这会导致一个人重新思考他们对某些关键概念的重视程度，比以前更看重某些概念，而认为其他概念不那么重要了呢。[1] 这些概念和观念不限于此，但一般包括这些喵：

个人使命感的增强。[2]
对追求发展个人宗教和精神意识形态的兴趣增加。[3][4]
- 形成复杂的个人宗教信仰。
对自然和他人的同情心增强。[3][4][5]
自身、自然、“神”和整个宇宙之间的统一感与相互连接感增强。[1][3][5][6][7][8][9]
对金钱和物质的重视程度降低。[5]
对死亡和存在的有限性的恐惧减少，接受度提高。[1][10][11]

虽然因为灵性增强的主观性，很难完全讲清楚，但这些信仰体系的改变通常会导致一个人性格的深刻变化喵，[5][7][12] 这种变化有时对他身边的人来说是非常明显的。这种转变可能会突然发生，但通常随着一个人重复使用诱发这种转变的精神活性物质而逐渐增加。

灵性增强不太可能是一个孤立的效应，而是在适当的情景与心境下，结合其他伴随效应的结果，[3] 比如分析能力增强、自主声音交流、新奇感增强、对立统一感知、宿命论感知、自我设计感、个人偏见抑制和统一感与相互连接感。它最常在中等剂量的致幻剂类化合物影响下产生，比如LSD、赛洛西宾和麦斯卡林。不过呢，在解离剂的影响下，如氯胺酮、PCP和右美沙芬，也会发生程度较轻的这种情况哦。

分析

有许多深入的科学研究一致支持致幻剂使用所诱发的精神效应是真实存在的喵。[1][3][4][5][6][7][8][9][12][13][14][15][16][17][18][19]

通常，新的迷幻剂使用者会将他们的体验评为一生中最有意义的单一体验，或者是前五名最有意义的体验之一呢。[4][6][10][12]

任何有意用于宗教或精神目的的迷幻剂或致幻剂在文献中被称为神圣致幻剂（Entheogen）。[3][20] 为了宗教或精神目的而仪式性地使用神圣致幻剂可以追溯到几千年前，并且在人类学和现代证据中都得到了很好的证实哦。[3][4][5][12][15][17][21][22][23][24][25][26][27]

体验报告

在我们的体验索引中描述这种效应的轶事报告包括：

Experience: 1 tab 1P-LSD (oral) - Finding myself within the forest_-_Finding_myself_within_the_forest)
Experience: 22mg 2C-B (oral) / 100ug 1P-LSD (sublingual) - My first time tripping alone (2 days in a row)/_100ug_1P-LSD(sublingual)-_My_first_time_tripping_alone(2_days_in_a_row))
Experience:1.5 Grams Psilocybe Cubensis
Experience:10mg & 20mg Intravenous DPT HCl - Familiar Shapes, Experiencing Death, Immersed in The Light
Experience:2 grams Psilocybe Cubensis + 2.7 grams Syrian Rue - The Psilohuasca Albino Fox
Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
Experience:300ug LSD - Profound religious experience
Experience:30mg (smoked) DMT - The Monolith_DMT_-_The_Monolith)
Experience:400ug LSD + weed + nitrous -- Fundamental insights into the universe
Experience:40mg + Syrian Rue (unknown dosage) - My one bad trip_-_My_one_bad_trip)
Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria
Experience:LSA (20 HWBR seeds) – A pleasant adventure with a harsh body load_%E2%80%93_A_pleasant_adventure_with_a_harsh_body_load)
Experience:LSD (150µg) + Cannabis - 150µg lsd and a shitload of weed_%2B_Cannabis_-_150%C2%B5g_lsd_and_a_shitload_of_weed)
Experience:LSD (230 ug) - An amazing adventure by vikilikepsych_-_An_amazing_adventure_by_vikilikepsych)
Experience:LSD (400ug, Oral) - An afternoon in "a" garden_-An_afternoon_in%22a%22_garden)
Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams))
Experience:Unknown dosage / 1 tabs - Prolonged unity and messiah syndrome at school

另见

外部链接

参考文献

(此处保留原文参考文献链接，因不涉及PsychonautWiki内链) 1. 1.0 1.1 1.2 1.3 Gasser, P., Kirchner, K., Passie, T. (January 2015). "LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects". Journal of Psychopharmacology. 29 (1): 57–68. 2. Peterman, A. H., Fitchett, G., Brady, M. J., Hernandez, L., Cella, D. (February 2002). "Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp)". Annals of Behavioral Medicine. 24 (1): 49–58. 3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Trichter, S., Klimo, J., Krippner, S. (June 2009). "Changes in Spirituality Among Ayahuasca Ceremony Novice Participants". Journal of Psychoactive Drugs. 41 (2): 121–134. 4. 4.0 4.1 4.2 4.3 4.4 Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., Jesse, R. (December 2011). "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects". Psychopharmacology. 218 (4): 649–665. 5. 5.0 5.1 5.2 5.3 5.4 5.5 Lerner, M., Lyvers, M. (June 2006). "Values and Beliefs of Psychedelic Drug Users: A Cross-Cultural Study". Journal of Psychoactive Drugs. 38 (2): 143–147. 6. 6.0 6.1 6.2 Griffiths, R. R., Richards, W. A., McCann, U., Jesse, R. (August 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. 7. 7.0 7.1 7.2 MacLean, K. A., Johnson, M. W., Griffiths, R. R. (November 2011). "Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness". Journal of Psychopharmacology. 25 (11): 1453–1461. 8. 8.0 8.1 Kometer, M., Pokorny, T., Seifritz, E., Volleinweider, F. X. (October 2015). "Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations". Psychopharmacology. 232 (19): 3663–3676. 9. 9.0 9.1 Lyvers, M., Meester, M. (1 November 2012). "Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner". Journal of Psychoactive Drugs. 44 (5): 410–417. 10. 10.0 10.1 Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., Schmidt, B. L. (December 2016). "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial". Journal of Psychopharmacology. 30 (12): 1165–1180. 11. Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., Greer, G. R. (3 January 2011). "Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer". Archives of General Psychiatry. 68 (1): 71. 12. 12.0 12.1 12.2 12.3 Studerus, E., Kometer, M., Hasler, F., Vollenweider, F. X. (November 2011). "Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies". Journal of Psychopharmacology. 25 (11): 1434–1452. 13. Cummins, C., Lyke, J. (April 2013). "Peak Experiences of Psilocybin Users and Non-Users". Journal of Psychoactive Drugs. 45 (2): 189–194. 14. Griffiths, R., Richards, W., Johnson, M., McCann, U., Jesse, R. (August 2008). "Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later". Journal of Psychopharmacology. 22 (6): 621–632. 15. 15.0 15.1 Bakalar, J. B. (October 1985). "Social and Intellectual Attitudes Toward Drug-Induced Religious Experience". Journal of Humanistic Psychology. 25 (4): 45–66. 16. Móró, L., Simon, K., Bárd, I., Rácz, J. (July 2011). "Voice of the Psychonauts: Coping, Life Purpose, and Spirituality in Psychedelic Drug Users". Journal of Psychoactive Drugs. 43 (3): 188–198. 17. 17.0 17.1 Nichols, D. E. (April 2016). Barker, E. L., ed. "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. 18. Luke, D. (1 January 2012). "Psychoactive Substances and Paranormal Phenomena: A Comprehensive Review". International Journal of Transpersonal Studies. 31 (1): 97–156. 19. Luke, D., Kittenis, M. (2005). "A preliminary survey of paranormal experiences with psychoactive drugs" (PDF). Journal of Parapsychology. 69: 305–327. 20. Ruck, C. A. P., Bigwood, J., Staples, D., Ott, J., Wasson, R. G. (January 1979). "Entheogens". Journal of Psychedelic Drugs. 11 (1–2): 145–146. 21. Guzmán, G. (November 2008). "Hallucinogenic Mushrooms in Mexico: An Overview". Economic Botany. 62 (3): 404–412. 22. Bruhn, J. G., De Smet, P. A., El-Seedi, H. R., Beck, O. (May 2002). "Mescaline use for 5700 years". The Lancet. 359 (9320): 1866. 23. El-Seedi, H. R., Smet, P. A. G. M. D., Beck, O., Possnert, G., Bruhn, J. G. (October 2005). "Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas". Journal of Ethnopharmacology. 101 (1–3): 238–242. 24. Pettigrew, J. (1 September 2011). "Iconography in Bradshawb rock art: breaking the circularity". Clinical and Experimental Optometry. 94 (5): 403–417. 25. Carod-Artal, F. J. (January 2015). "Alucinógenos en las culturas precolombinas mesoamericanas". Neurología. 30 (1): 42–49. 26. Wasson, R. G. (April 1971). "The Soma of the Rig Veda: What Was It?". Journal of the American Oriental Society. 91 (2): 169. 27. Rios, M. D. de (July 1977). "Hallucinogenic Ritual as Theatre". Journal of Psychedelic Drugs. 9 (3): 265–268.